RxDoctor Payments Data

Elizabeth Kirchner

Nurse Practitioner · Cleveland, OHNPI 1356446967

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (55.7%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 12 manufacturers reported payments, led by Johnson & Johnson at 27.4% of the total. Among nurse practitioner clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$27,127in general payments, 2019–2025

Across 81 payments — averaging $334.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$7K
  • Eli Lilly$7K
  • UCB, Inc.$6K
  • AstraZeneca$2K
  • Pfizer$1K
  • E.r. Squibb & Sons, L.L.C.$1K
  • plus $2K from 6 others

What the payments were for

  • Consulting fees$15,11356%
  • Speaking & faculty fees$7,68828%
  • Travel & lodging$2,1978%
  • Food & beverage$2,0578%
  • Education$730%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$27,127 in reported general payments places this provider in the 95th percentile of 4,700 nurse practitioner providers in Ohio.

See all nurse practitioner providers in Ohio

Medicare billing

Part B allowed, 2024
$36,508
Medicare patients
292
Services billed
640

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OdefseyEmtricitab/Rilpiviri/Tenof Ala40$171,857
Enbrel SureclickEtanercept22$160,218
Humira(Cf) PenAdalimumab15$121,079
DescovyEmtricitabine/Tenofov Alafenam52$115,155
XeljanzTofacitinib Citrate14$93,187
RinvoqUpadacitinib15$87,816
BiktarvyBictegrav/Emtricit/Tenofov Ala18$73,425
GenvoyaElviteg/Cob/Emtri/Tenof Alafen18$69,527
TivicayDolutegravir Sodium16$64,043
ForteoTeriparatide13$54,872
Teriparatide18$50,537
JulucaDolutegravir/Rilpivirine14$47,369
IsentressRaltegravir Potassium24$46,124
Efavirenz19$11,955
Darunavir14$11,147

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerXeljanz$1,250$93,18714 claims
AbbVieRinvoq$283$87,81615 claims
Lilly USA, LLCForteo$531$54,87213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,700 nurse practitioner providers in Ohio.

Other nurse practitioner in Cleveland

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →